VRXA Stock Forecast: VERAXA Biotech AG Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores VERAXA Biotech AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (56): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VRXA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VRXA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
VRXA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VRXA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, VERAXA Biotech AG returned −90.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VRXA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 6277.8×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 1% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- 66.0%
Higher than 97% of US stocks
- Return on equity
- —
- Return on assets
- −50.0%
- Dividend yield
- —
Higher than 8% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
VERAXA Biotech AG has a market value of $147.1M and an enterprise value of $147.6M.
Data provided by Twelve Data
VRXA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VRXA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own VERAXA Biotech AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VRXA
How does Ticker Nerd's model rank VRXA?
As at 21 Nov 2026, VERAXA Biotech AG ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (56 of 100).
What is the VRXA stock forecast for 2030?
No analyst covering VERAXA Biotech AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRXA are extrapolating price history, which says nothing about the business.
How has VRXA stock performed over the past year?
VERAXA Biotech AG returned -90.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does VERAXA Biotech AG do?
Veraxa Biotech AG is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer therapies. The company works on antibody-drug conjugates and bispecific antibody formats, using proprietary screening and bioconjugation technologies to create targeted oncology candidates.
About VERAXA Biotech AG.
Veraxa Biotech AG is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer therapies. The company works on antibody-drug conjugates and bispecific antibody formats, using proprietary screening and bioconjugation technologies to create targeted oncology candidates. Its current pipeline centers on drug programs in acute myeloid leukemia and other cancer indications, reflecting a focus on precise, mechanism-driven treatment approaches. Veraxa Biotech AG also develops platform capabilities intended to support the identification, engineering, and optimization of therapeutic antibodies for internal programs and collaborative partnerships. Based in Zurich, Switzerland, with research and development operations in Heidelberg, Germany, the company operates within the oncology biotechnology market and contributes to the broader advancement of next-generation biologic medicines.
CEO Dr. Christoph Antz Ph.D. · Switzerland · https://www.veraxa.com